Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Bone Marrow Transplantation

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bmt.2014.99PMID 24842529
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cited by this paper
• Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.

  2013cited by this paper
• Minimal residual disease in acute myeloid leukaemia

  2013cited by this paper
• Should evaluation for minimal residual disease be routine in acute myeloid leukemia?

  2013cited by this paper
• Critical assessment of automated flow cytometry data analysis techniques

  2013cited by this paper
• Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity

  2013cited by this paper
• New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia.

  2013cited by this paper
• Relapsed acute myeloid leukemia: why is there no standard of care?

  2013cited by this paper
• Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis

  2013cited by this paper
• Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

  2013cited by this paper
• Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting

  2013cited by this paper
• Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

  2012cited by this paper
• The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse

  2012cited by this paper
• Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

  2012cited by this paper
• Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

  2012cited by this paper
• Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission – methodologies in relation to their clinical situation

  2012cited by this paper
• Minimal residual disease in acute myeloid leukemia: coming of age.

  2012cited by this paper
• Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

  2012cited by this paper
• Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data

  2012cited by this paper
• A novel hierarchical prognostic model of AML solely based on molecular mutations.

  2012cited by this paper
• Towards individualized follow-up in adult acute myeloid leukemia in remission.

  2011cited by this paper
• Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management

  2011cited by this paper
• Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10

  2011cited by this paper
• Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells

  2011cited by this paper
• Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.

  2011cited by this paper
• Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia.

  2010cited by this paper
• Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

  2010cited by this paper
• Assessment of minimal residual disease in acute myeloid leukemia

  2010cited by this paper
• Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia

  2009cited by this paper
• Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

  2009cited by this paper
• Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

  2009cited by this paper
• CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

  2009cited by this paper
• The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.

  2009cited by this paper
• The use of receiver operating characteristic analysis for detection of minimal residual disease using five‐color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse

  2009cited by this paper
• Development of minimal residual disease-directed therapy in acute myeloid leukemia.

  2008cited by this paper
• A Multidimensional Classification Approach for the Automated Analysis of Flow Cytometry Data

  2008cited by this paper
• Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

  2008cited by this paper
• Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.

  2008cited by this paper
• Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.

  2006cited by this paper
• High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

  2006cited by this paper
• The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.

  2005cited by this paper
• Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring

  2005cited by this paper
• Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.

  2004cited by this paper
• Multicolor immunophenotyping: human immune system hematopoiesis.

  2004cited by this paper
• Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

  2004cited by this paper
• Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.

  2004cited by this paper
• Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.

  2003cited by this paper
• Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.

  2002cited by this paper
• Human hematopoietic lineage commitment

  2002cited by this paper
• Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients

  2002cited by this paper
• Immunophenotypic analysis with enhanced sensitivity of detection by enzymatic amplification staining.

  2001cited by this paper
• Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.

  2001cited by this paper
• High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).

  2001cited by this paper
• Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.

  2000cited by this paper
• Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia.

  2000cited by this paper
• Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

  1997cited by this paper
• Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.

  1997cited by this paper
• Characterization of aberrant phenotypes in acute myeloblastic leukemia

  1995cited by this paper
• Expression of unusual immunophenotype combinations in acute myelogenous leukemia.

  1993cited by this paper
• Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells.

  1992cited by this paper
• Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.

  1992cited by this paper
• Selected pharmacologic characteristics of idarubicin and idarubicinol.

  1992cited by this paper
• Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.

  1992cited by this paper
• Proceedings: Surface antigens of leukaemic cells.

  1975cited by this paper
• Specificity of heteroantisera to human acute leukemia-associated antigens.

  1974cited by this paper
• Leukaemia Antigens and Immunity in Man

  1973cited by this paper

• Disentangling Coincident Cell Events Using Deep Transfer Learning and Compressive Sensing

  2025cites this paper
• Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

  2025cites this paper
• 4-Color Flow Cytometric Crossmatch Using Whole Blood Lysis.

  2024cites this paper
• A simplified and robust risk stratification model for stem cell transplantation in pediatric acute myeloid leukemia

  2024cites this paper
• Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML

  2024cites this paper
• Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection

  2023cites this paper
• Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia.

  2023cites this paper
• Evaluation and validation of the prognostic value of platelet indices in patients with leukemia

  2023cites this paper
• Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia‐related changes: A single institution experience

  2022cites this paper
• Methodological aspects of the detection of minimal residual disease in patients with acute leukemia

  2022cites this paper
• The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation

  2022cites this paper
• Comparison of flow cytometry and next‐generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: One institute’s practical clinical experience

  2021cites this paper
• Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia

  2021cites this paper
• Calibration-free NGS quantitation of mutations below 0.01% VAF

  2021cites this paper
• Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML.

  2020cites this paper
• Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients

  2020cites this paper
• Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis

  2020cites this paper
• Chimerism evaluation in measurable residual disease‐suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation

  2020influential citation
• Could Immunophenotype Guide Molecular Analysis in Patients with Myeloid Malignancies

  2019cites this paper
• Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia.

  2019cites this paper
• Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes.

  2019cites this paper
• Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group

  2019cites this paper
• Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes.

  2019cites this paper
• Identifying leukemia‐associated immunophenotype‐based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance

  2019cites this paper
• Measurable residual disease testing for personalized treatment of acute myeloid leukemia

  2019cites this paper
• Microfluidic Device for On-Chip Immunophenotyping and Cytogenetic Analysis of Rare Biological Cells

  2019cites this paper
• Current status and trends in the diagnostics of AML and MDS.

  2018cites this paper
• University of Birmingham Role of minimal (measurable) residual disease assessment in older patients with acute myeloid leukemia

  2018cites this paper
• Improved protocol for simultaneous analysis of leukocyte subsets and epithelial cells from murine and human lung

  2018cites this paper
• Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.

  2018cites this paper
• Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia

  2018cites this paper
• Methods and role of minimal residual disease after stem cell transplantation

  2018cites this paper
• Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization

  2018cites this paper
• Assessment of Minimal Residual Disease by Flow Cytometry in Acute Myeloid Leukaemia and its Correlation with Treatment Outcome

  2018cites this paper
• Application of Molecular Karyotyping in Acute Myeloid Leukemia: A Review

  2018cites this paper
• Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

  2017cites this paper
• Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

  2017cites this paper
• Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

  2017cites this paper
• Aligning the flow cytometric evaluation with the diagnostic need: an evidence-based approach

  2017cites this paper
• Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia

  2017cites this paper
• Minimal residual disease in acute myelogenous leukemia

  2017cites this paper
• Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.

  2017cites this paper
• 多参数流式细胞术检测急性白血病及浆细胞肿瘤微小残留病中国专家共识（2017年版）

  2017cites this paper
• Automated Instrument Setup and Compensation on the BD FACSLyric ™ Flow Cytometer

  2017cites this paper
• Expression of Immune Checkpoint Receptors on Peripheral Blood Immune Cells Using a 10-Color Assay on the BD FACSLyric ™ Flow Cytometer

  2017cites this paper
• Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO‐AML 2004 study

  2016cites this paper
• Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia

  2016influential citation
• Znaczenie prognostyczne minimalnej choroby resztkowej ocenianej metodą cytometrii przepływowej w ostrej białaczce szpikowej

  2016influential citation
• Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia

  2016cites this paper
• Flow Cytometric Analysis of Myeloid Cells in Human Blood, Bronchoalveolar Lavage, and Lung Tissues.

  2016cites this paper
• Acute myeloid leukemia: 2016 Update on risk‐stratification and management

  2016cites this paper
• Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.

  2016cites this paper
• Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.

  2016cites this paper
• Blood group antigen studies using CdTe quantum dots and flow cytometry

  2015cites this paper
• Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients.

  2015cites this paper
• Development and Characterisation of AML-M5-Derived Induced Pluripotent Stem Cells (IPSCS)

  2015cites this paper
• ew approaches to understanding the immune response to accination and infection

  2015cites this paper
• Introducing minimal residual disease in acute myeloid leukemia

  2015cites this paper
• New approaches to understanding the immune response to vaccination and infection.

  2015cites this paper
• Isolation of Leukocytes from the Human Maternal-fetal Interface.

  2015cites this paper
• The role of multiparametric flow cytometry in the detection of minimal residual disease in acute leukaemia

  2015cites this paper
• The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia

  2015cites this paper
• A multigene array for measurable residual disease detection in AML patients undergoing SCT

  2015cites this paper
• Acute myeloid leukemia: 2014 Update on risk‐stratification and management

  2014cites this paper
• Immunobiology of Acute Leukemia

  2013cites this paper